The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.m

Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

Publications

Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, Ikeda Y

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical h

International journal of hematology 2006 Dec;84;406-12 — 2006 Dec — 406-12

Ohri A, Arena FP

Severe pulmonary complications in African-American patient after bortezomib therapy.

American journal of therapeutics 2006 Nov-Dec;13;553-5 — 2006 Nov-Dec — 553-5

Boyer JE, Batra RB, Ascensao JL, Schechter GP

Severe pulmonary complication after bortezomib treatment for multiple myeloma.

Blood 2006 Aug 01;108;1113 — 2006 Aug 01 — 1113